Market Research Logo

Dilated Cardiomyopathy - Pipeline Review, H2 2015

Dilated Cardiomyopathy - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Dilated Cardiomyopathy - Pipeline Review, H2 2015’, provides an overview of the Dilated Cardiomyopathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dilated Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dilated Cardiomyopathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Dilated Cardiomyopathy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Dilated Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Dilated Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Dilated Cardiomyopathy Overview
Therapeutics Development
Pipeline Products for Dilated Cardiomyopathy - Overview
Pipeline Products for Dilated Cardiomyopathy - Comparative Analysis
Dilated Cardiomyopathy - Therapeutics under Development by Companies
Dilated Cardiomyopathy - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Dilated Cardiomyopathy - Products under Development by Companies
Dilated Cardiomyopathy - Companies Involved in Therapeutics Development
Array BioPharma Inc.
Hemostemix Ltd
Kasiak Research Private Limited
Sanofi
Vericel Corporation
Dilated Cardiomyopathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARRY-797 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAP-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ixmyelocel-T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Refacell-DCM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dilated Cardiomyopathy - Recent Pipeline Updates
Dilated Cardiomyopathy - Dormant Projects
Dilated Cardiomyopathy - Product Development Milestones
Featured News & Press Releases
Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T
Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T
Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting
May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients
May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions
Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T
Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy
Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dilated Cardiomyopathy, H2 2015
Number of Products under Development for Dilated Cardiomyopathy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc., H2 2015
Dilated Cardiomyopathy - Pipeline by Hemostemix Ltd, H2 2015
Dilated Cardiomyopathy - Pipeline by Kasiak Research Private Limited, H2 2015
Dilated Cardiomyopathy - Pipeline by Sanofi, H2 2015
Dilated Cardiomyopathy - Pipeline by Vericel Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Dilated Cardiomyopathy Therapeutics - Recent Pipeline Updates, H2 2015
Dilated Cardiomyopathy - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Dilated Cardiomyopathy, H2 2015
Number of Products under Development for Dilated Cardiomyopathy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report